Non Muscle Invasive Bladder Cancer Clinical Trial
Official title:
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
An opened label trial designed to evaluate CG0070 and DDM in combination with Pembrolizumab in patients with NMIBC who have failed prior BCG therapy. The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1 papillary disease will be enrolled. BCG failure is defined as persistent or recurrent disease within 12 months of completion of adequate BCG therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06020807 -
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
|
||
Recruiting |
NCT04452591 -
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
|
Phase 3 | |
Recruiting |
NCT06167356 -
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
|
||
Withdrawn |
NCT01799499 -
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
|
N/A | |
Completed |
NCT02343614 -
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05945108 -
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
|
||
Recruiting |
NCT06287541 -
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
|
N/A | |
Recruiting |
NCT06181266 -
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
|
Phase 1 | |
Terminated |
NCT02982395 -
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
|
Phase 3 | |
Completed |
NCT06205277 -
Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT01731652 -
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT03421236 -
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
Recruiting |
NCT06111235 -
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
|
Phase 3 | |
Recruiting |
NCT02895620 -
Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC
|
N/A | |
Completed |
NCT01004211 -
Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging
|
N/A | |
Active, not recruiting |
NCT05981131 -
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
|